AstraZeneca ((AZN +0.7%) gets a bump higher from a Jefferies upgrade to Buy, despite the...


AstraZeneca ((AZN +0.7%) gets a bump higher from a Jefferies upgrade to Buy, despite the company's weaK Q1 revenue results last week. The firm says market expectations are too high on the revenue side, noting the company's attractive dividend yield should be a positive catalyst for the shares.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs